About Abrdn Healthcare Investors
https://www.teklacap.com/hqh.htmlAbrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies.
CEO
Daniel R. Omstead
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
MORGAN STANLEY
Shares:4.2M
Value:$80.59M
PENSERRA CAPITAL MANAGEMENT LLC
Shares:1.2M
Value:$22.99M
RAYMOND JAMES FINANCIAL INC
Shares:1.19M
Value:$22.75M
Summary
Showing Top 3 of 156
About Abrdn Healthcare Investors
https://www.teklacap.com/hqh.htmlAbrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2024 | $5.46M ▲ | $5.65M ▲ | $85.25M ▼ | 1.56K% ▼ | $1.59 ▼ | $0 |
| Q2-2024 | $5.31M ▲ | $5.34M ▼ | $99.7M ▲ | 1.88K% ▲ | $1.97 ▲ | $0 |
| Q4-2023 | $4.66M ▼ | $5.69M ▼ | $-26.83M ▼ | -575.22% ▼ | $-0.53 ▼ | $0 |
| Q2-2023 | $5.63M ▲ | $5.79M ▲ | $83.16M ▲ | 1.48K% ▲ | $1.72 ▲ | $0 |
| Q4-2022 | $4.32M | $5.75M | $-79.18M | -1.83K% | $-1.64 | $0 |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2024 | $56 ▼ | $1.06B ▲ | $1.4M ▲ | $1.06B ▲ |
| Q2-2024 | $14.1K ▲ | $1.01B ▲ | $1.11M ▼ | $1.01B ▲ |
| Q4-2023 | $214 ▼ | $932.49M ▼ | $1.15M ▼ | $931.34M ▼ |
| Q2-2023 | $1.05K ▲ | $990.76M ▲ | $11.68M ▲ | $979.09M ▲ |
| Q4-2022 | $792 | $926.28M | $9.71M | $916.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2024 | $85.25M ▼ | $8.72M ▲ | $0 | $-8.72M ▼ | $0 | $8.72M ▲ |
| Q2-2024 | $99.7M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q4-2023 | $-26.83M ▼ | $0 | $0 | $0 | $0 | $0 |
| Q2-2023 | $83.16M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q4-2022 | $-79.18M | $0 | $0 | $0 | $0 | $0 |
CEO
Daniel R. Omstead
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
MORGAN STANLEY
Shares:4.2M
Value:$80.59M
PENSERRA CAPITAL MANAGEMENT LLC
Shares:1.2M
Value:$22.99M
RAYMOND JAMES FINANCIAL INC
Shares:1.19M
Value:$22.75M
Summary
Showing Top 3 of 156